Conquering Scientific Challenges to Combat Cancer

Our company

Established in 2017, NiKang Therapeutics™ is a clinical-stage biotech company dedicated to developing innovative small molecule drugs.

Our research relies on disease biology insights and structure-based drug design with a current focus on HIF2α, CDK2 and KRAS.

Our mission is to develop precision medicine to address highly unmet medical needs, such as cancer.

Our Science

Our target selection is based on disease biology insights and molecular pathways. Our compound discovery is built on target structural biology and structure-based drug design. We employ modality-agnostic approaches to create medicines with optimal pharmacological profile. Our strategy involves selectively and maximally modulating pathways to unlock the full potential of validated targets.

Since 2017, scientists at NiKang have advanced three small molecule drugs into first-in-human clinical testing for new cancer treatment, against difficult-to-drug targets: SHP2, HIF2a, CDK2.

Find out more about our scientific approach and study pipeline.

Company News

Follow our remarkable journey on our quest to conquer challenges and combat cancer.

NiKang Therapeutics Doses First Patient in a Phase 1/1b Study of NKT3447, an Oral, Selective Inhibitor of CDK2 Which Reduces Cyclin E Expression

Read more

NiKang Therapeutics Presents the Discovery and Unique Mechanism of Action of a Selective CDK2 Inhibitor NKT3447 at AACR Annual Meeting 2024

Read more

NiKang Therapeutics Appoints Joanne Lager,M.D., as Chief Medical Officer

Read more